Breakthrough Discoveries.
Breakthrough Discoveries.
Pioneering ALS therapeutics.
Pioneering ALS therapeutics.
Pioneering first-in-class treatments targeting PEG10, a newly discovered driver of ALS and neurodevelopmental disorders.
Pioneering first-in-class treatments targeting PEG10, a newly discovered driver of ALS and neurodevelopmental disorders.
Innovative Solutions for ALS and Rare Neurological Disorders
Innovative Solutions for ALS and Rare Neurological Disorders
Endios Bio develops novel therapeutics for ALS and rare neurological diseases based on breakthrough discoveries from Harvard Medical School and the University of Colorado Boulder, CU Boulder.
Endios Bio develops novel therapeutics for ALS and rare neurological diseases based on breakthrough discoveries from Harvard Medical School and the University of Colorado Boulder, CU Boulder.
Founded through CU Boulder’s Embark Deep Tech Startup Creator, we translate pioneering molecular biology into real-world therapeutics. We are targeting unexplored disease mechanisms to bring new hope to patients with limited treatment options.
Founded through CU Boulder’s Embark Deep Tech Startup Creator, we translate pioneering molecular biology into real-world therapeutics. We are targeting unexplored disease mechanisms to bring new hope to patients with limited treatment options.
Our Science
Our Science
Endios Bio Identifies PEG10 as New ALS Player
Drives Early ALS Progression
PEG10 is an upstream factor in ALS, triggering early molecular changes that drive disease progression.
Drives Early ALS Progression
PEG10 is an upstream factor in ALS, triggering early molecular changes that drive disease progression.
Drives Early ALS Progression
PEG10 is an upstream factor in ALS, triggering early molecular changes that drive disease progression.
Abundant in ALS Spinal Tissue
PEG10 is dramatically accumulated in ALS spinal cords comparing more than 7,000 proteins.
Abundant in ALS Spinal Tissue
PEG10 is dramatically accumulated in ALS spinal cords comparing more than 7,000 proteins.
Abundant in ALS Spinal Tissue
PEG10 is dramatically accumulated in ALS spinal cords comparing more than 7,000 proteins.
Disrupts Gene Expression Pathways
PEG10 self-cleaves into toxic particles—altering gene expression and contributing to neurodegeneration.
Disrupts Gene Expression Pathways
PEG10 self-cleaves into toxic particles—altering gene expression and contributing to neurodegeneration.
Disrupts Gene Expression Pathways
PEG10 self-cleaves into toxic particles—altering gene expression and contributing to neurodegeneration.
Therapeutic Pipeline
Therapeutic Approach
Our dual approach addresses both production and toxicity, opening multiple therapeutic paths for treating ALS and related conditions.
Endios Bio is developing two patented therapeutic programs aimed at neutralizing PEG10:
dna strands
Blocks PEG10 translation at the RNA level—halts its production and impact.
dna strands
Blocks PEG10 translation at the RNA level—halts its production and impact.
small molecules
Targets PEG10’s toxic activity by preventing self-cleavage and disease progression.
small molecules
Targets PEG10’s toxic activity by preventing self-cleavage and disease progression.
Stay Connected
Join our Newsletter
Get scientific updates, company news, and therapeutic progress delivered to your inbox. Subscribe to the Endios Bio newsletter.